Amino-pyrimidine skeletal muscle modulators
Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
1. A method for treating a disease or condition selected from the group consisting of neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), myasthenia gravis, peripheral vascular disease, peripheral arterial disease, chronic pulmonary obstructive disorder (COPD), heart failure, frailty, and obesity, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the disease or condition is Amyotrophic Lateral Sclerosis (ALS).
3. The method of claim 1 , wherein the disease or condition is Spinal Muscular Atrophy (SMA).
4. The method of claim 1 , wherein the disease or condition is myasthenia gravis.
5. The method of claim 1 , wherein the disease or condition is peripheral vascular disease or peripheral arterial disease.
6. The method of claim 1 , wherein the disease or condition is chronic pulmonary obstructive disorder (COPD).
7. The method of claim 1 , wherein the disease or condition is heart failure.
8. The method of claim 1 , wherein the disease or condition is frailty.